Traders Purchase Large Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) saw some unusual options trading on Tuesday. Traders bought 18,509 call options on the company. This represents an increase of approximately 190% compared to the average volume of 6,379 call options.

More Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA review extension provides additional time. The FDA extended the PDUFA target action date for deramiocel, Capricor’s investigational therapy for Duchenne muscular dystrophy, to November 22, 2026. The extension follows Capricor’s submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication. The added time may allow regulators to evaluate the new information and gives Capricor an opportunity to address review issues. Capricor FDA review extension
• Positive Sentiment: Oppenheimer upgraded CAPR. The firm raised its rating from “Market Perform” to “Outperform,” citing optimism surrounding potential approval of deramiocel. The upgrade likely helped support buying interest. Oppenheimer CAPR upgrade
• Neutral Sentiment: Options activity surged. Investors bought 18,509 call options, about 190% above average call volume, indicating increased speculative interest and potentially bullish positioning. However, options activity does not guarantee sustained share-price gains.
• Negative Sentiment: Several law firms publicized a securities-fraud class action. The lawsuit covers investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, with a September 28, 2026 deadline to seek lead-plaintiff status. Allegations include misleading statements or omissions involving deramiocel’s approval path, the HOPE-3 statistical analysis plan, FDA compliance, and clinical-data integrity. These are allegations, not established findings, but the litigation adds reputational, financial, and regulatory risk. Capricor securities-fraud lawsuit

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock opened at $8.29 on Wednesday. The business has a 50-day moving average of $15.57 and a 200 day moving average of $24.61. Capricor Therapeutics has a 12 month low of $2.96 and a 12 month high of $40.37. The stock has a market capitalization of $481.98 million, a price-to-earnings ratio of -3.38 and a beta of 0.54.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). Equities research analysts anticipate that Capricor Therapeutics will post -1.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CAPR has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Piper Sandler cut shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 price target for the company. in a research report on Thursday, July 30th. Oppenheimer upgraded shares of Capricor Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Friday, August 14th. Finally, LADENBURG THALM/SH SH cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $29.15.

Insider Activity at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at $340,954.74. This represents a 68.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 25,000 shares of company stock valued at $759,158. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CAPR. Russell Investments Group Ltd. grew its stake in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 2,786 shares in the last quarter. ACT Capital Management LLC purchased a new position in Capricor Therapeutics in the fourth quarter valued at $43,000. KBC Group NV purchased a new position in Capricor Therapeutics in the first quarter valued at $44,000. Tower Research Capital LLC TRC grew its stake in Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares in the last quarter. Finally, Regal Investment Advisors LLC purchased a new stake in Capricor Therapeutics during the 3rd quarter worth about $92,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.